Close Menu

Industry Briefs: Feb 26, 2009

Premium

Mosaiques, FDA Partner on Drug-Toxicity Biomarker Deal

German firm Mosaiques said last week it is collaborating with the US Food and Drug Administration to discover and validate protein and peptide biomarkers indicative of drug toxicity in urine.

Under the agreement, Mosaiques will provide guidance on proteome analysis, especially the preparation of urine and capillary electrophoresis-coupled mass spectrometry; data evaluation; calibration; and multivariate statistics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.

Sep
09
Sponsored by
10x Genomics

Recent advances in spatially resolved transcriptomics have greatly expanded the knowledge of complex multicellular biological systems.